2. Grinsztejn B, et al, Lancet Infect Dis, March 4 th 2014 PRIMARY COMBINED M&M OUTCOME FIRST AIDS DEFINING EVENT FIRST TB EVENT DEATH

3. Impact of ART on Life Expectancy Bor et al, Science 2013

4. ART and Employment Bor et al, Health Affairs 2012

6. Mortality & ART Coverage Modified from A. Hill et al. IAS 2014 [LBPE29]

7. New HIV infections* & ART Coverage Modified from A. Hill et al. IAS 2014 [LBPE29] * percentage growth

8. HIV Transmission According to Sexual Behavior Reported by HIV-Negative Partner Rate of Couple Transmission (per 100 Couple-Years Follow-Up) Heterosexual (Male) Vaginal sex with ejaculation (192 CYFU) Heterosexual (Female) Vaginal sex (272 CYFU) MSM Receptive anal sex: With ejaculation (93 CYFU) Without ejaculation (157 CYFU) Insertive anal sex (262 CYFU) 0 1 2 3 4 Rate (95% CI) Overall risk = Zero through condomless sex with a partner on ART (HIV RNA <200 copies/mL Rodger A, et al. 21 st CROI. Boston, 2014. Abstract 153LB.

10. Key Messages TasP is primarily about Preventing Morbidity & Mortality, and as a byproduct, for virtually no additional investment and in a cost-saving fashion, Preventing HIV Transmission TasP vs Chemoprophylaxis TasP works in all settings, including in MSM TasP works in RLMS 2013 WHO Guidelines Need for Ambitious New ART Targets – Proposed UNAIDS 90-90-90 Target

11. By 2020… 90% of all people living with HIV will know their HIV status 90% of all people diagnosed with HIV will receive sustained antiretroviral therapy. 90% of all people receiving antiretroviral therapy will have durable suppression.

12. The result = a three-fold increase over current 2014 estimates 72 % of all people living with HIV will be virally suppressed 3

13. The new treatment paradigm Single target → Cascade target Death → Death and transmission Number → Equity Incremental funding→ Frontload Investments

14. The objective “Maximize the effectiveness of existing tools to virtually eliminate progression to AIDS, premature death and HIV transmission, and thereby transform the HIV/AIDS pandemic into a low level sporadic endemic.”

15. For Further Information Invited Presentations Workshop Proceedings Evaluation Please visit the website: www.treatmentaspreventionworkshop.org